Quick Summary
- Gilead Sciences has entered a definitive agreement to purchase German biotech company Tubulis GmbH for a total consideration of up to $5 billion.
- The transaction includes an upfront cash payment of $3.15 billion plus additional milestone-based payments reaching $1.85 billion.
- This acquisition strengthens Gilead’s antibody-drug conjugate portfolio, with focus areas including ovarian and non-small cell lung cancers.
- RBC Capital Markets increased its GILD price target from $118 to $123 while maintaining a Sector Perform rating.
- Analysts project Yeztugo could exceed Q1 expectations by approximately $180 million, though concerns exist around compliance rates and market penetration.
- Multiple Wall Street firms including Cantor Fitzgerald, UBS, and Deutsche Bank maintain bullish stances with price targets reaching $155.
Gilead Sciences (GILD) is bolstering its oncology therapeutics portfolio through a strategic acquisition of Munich-headquartered Tubulis GmbH, valued at up to $5 billion in an all-cash transaction.
The pharmaceutical giant will pay $3.15 billion immediately upon closing, with an additional $1.85 billion contingent on achieving specific development and commercial milestones. Financing will come from existing cash reserves and newly issued senior unsecured notes, with the transaction anticipated to close during the second quarter of 2026.
Tubulis specializes in developing antibody-drug conjugates, an innovative cancer treatment approach that delivers chemotherapy agents directly to malignant cells while minimizing damage to surrounding healthy tissue. The company’s most advanced candidate, TUB-040, is currently undergoing Phase 1b/2 clinical testing for patients with platinum-resistant ovarian cancer and non-small cell lung cancer.
Chief Executive Officer Daniel O’Day characterized the enhanced pipeline as potentially representing the most robust and diversified collection of assets in Gilead’s corporate history.
Shares declined approximately 1.37% following Tuesday’s announcement, a common market response when corporations reveal substantial upfront capital commitments.
RBC Capital Increases Target While Maintaining Neutral Rating
RBC Capital Markets adjusted its GILD price objective upward to $123 from the previous $118 target, though the firm retained its Sector Perform rating — effectively a neutral recommendation. The investment bank highlighted encouraging early performance data for Yeztugo, one of Gilead’s recently launched therapeutics, based on third-party prescription monitoring.
RBC’s analysis suggests Yeztugo could surpass first-quarter consensus estimates by approximately $180 million, compared to Street expectations of $141 million. This would represent a substantial outperformance if realized.
However, RBC analysts also expressed some reservations. The firm noted that buy-side projections for calendar year 2026 may already incorporate approximately $1 billion in Yeztugo revenue. Should patient compliance rates or market penetration fall short, those optimistic peak sales forecasts could require downward revision.
Current compliance tracking stands at roughly 70% according to RBC’s channel checks — a respectable level, but one that offers limited cushion for deterioration.
RBC also identified potential headwinds in other business segments. The firm estimates HIV-related revenue at $4.8 billion versus consensus of $4.9 billion, while Veklury revenue is projected at $141 million compared to Street expectations of $216 million.
Gilead is scheduled to announce first-quarter financial results on April 23.
Wall Street Analysts Remain Largely Optimistic
Several other research firms maintain more constructive views. Cantor Fitzgerald reaffirmed its Overweight recommendation with a $155 price objective, highlighting robust prescription momentum across Gilead’s HIV franchise.
UBS also continues to rate the stock as a Buy, citing a 56% sequential monthly increase in Yeztugo sales during February. Deutsche Bank similarly maintained its Buy rating and $155 target, forecasting approximately $118 million in first-quarter Yeztugo revenue.
In a separate development, Gilead announced an extension of the tender offer deadline for Arcellx common shares to April 24, 2026. The proposal offers $115.00 per share in cash, supplemented by contingent value rights linked to future sales achievements.
With first-quarter earnings scheduled for April 23, market participants will be closely monitoring whether Yeztugo’s encouraging early performance translates into actual financial results that exceed expectations.
